Abstract
Background: Although several studies have determined quality of life in patients with lung cancer, there is still little information about the use of generic questionnaires [e.g. the 36-item Short Form health survey (SF-36)] and utility questionnaires [e.g. the EuroQOL instrument (EQ-5D)] in this disease.
Objectives: To (i) measure quality of life and utility in patients with non-small cell lung cancer (NSCLC) using the SF-36 and the EuroQOL questionnaires; (ii) to evaluate the impact of some clinical variables on quality of life and utility; (iii) to assess the correlation between the measurements produced by the 2 questionnaires.
Study design: Cross-sectional study.
Participants: 95 patients from15 Italian hospitals with NSCLC (93% male, mean age 62 years) completed both questionnaires.
Results: The mean scores for the 8 domains of the SF-36 ranged from 20.8 (physical role) to 63.0 (social functioning). The mean physical and mental summed scores of the SF-36 were 36.8 [standard deviation (SD) 9.8] and 43.0 (SD 11.5), respectively. The EuroQOL mean score was 0.58 (SD 0.32) in the self-classifier (SC) version and 0.58 (SD 0.20) in the visual analogue scale (VAS) version. Among the clinical variables that affected quality of life and utility, the presence of metastasis had the greatest impact: patients with metastasis had statistically significantly lower scores for 2 domains of the SF-36 (physical functioning, p = 0.009; bodily pain, p = 0.016), for the physical component summed score of the SF-36 (p = 0.015) and for both utility estimates (EuroQOL-SC, p = 0.027; EuroQOL-VAS, p = 0.038) than patients without metastasis. Both the SC and VAS EuroQOL scores showed a statistically significant correlation with each of the 8 domains of the SF-36. The scores for both the SF-36 and the EuroQOL in patients with NSCLC were considerably worse (relative differences ranging from −8 to −73%) than the corresponding values (normative data) previously reported for healthy individuals.
Conclusions: Our study quantified the degree to which quality of life is impaired in patients with NSCLC, showed that the presence of metastasis had an important role, and indicated a strong correlation between the measurements produced by the 2 questionnaires. The EuroQOL measurements obtained from these patients will aid evaluation of the cost-utility ratio for NSCLC therapies.
Similar content being viewed by others
References
Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998; 113 (2): 467–81
Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risks factors derived from quality of life data. J Clin Oncol 2000; 18 (4): 893–7
Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Caner Cooperative Group. J Clin Oncol 1998; 16 (6): 2133–41
Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998; 34 (7): 1036–44
Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. Br J Cancer 2000; 83 (4): 447–53
Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999; 7 (3): 140–8
Hollen PJ, Gralla RJ. Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 1996; 23 (2 Suppl. 5): 31–40
Ware Jr JE, Sherbourne JD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83
Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17 (1): 13–35
Arpinelli F, Visona G, Bruno R, et al. Health-related quality of life in asymptomatic patients with HIV: evaluation of the SF-36 health survey in Italian patients. Pharmacoeconomics 2000 Jul; 18 (1): 63–72
EuroQoL Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208
Kurtz ME, Kurtz JC, Stommel M, et al. Loss of physical functioning among geriatric cancer patients: relationships to cancer site, treatment, comorbidity and age. Eur J Cancer 1997; 33 (14): 2352–8
Mangione CM, Goldman L, Orav EJ, et al. Health-related quality of life after elective surgery: measurement of longitudinal changes. J Gen Intern Med 1997; 12 (11): 686–97
Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer 1999; 86 (9): 1848–55
Ware Jr JF, Kosnski M, Keller SD. SF-36 physical and mental health summary scales: a user’s manual. Boston (MA): The Health Institute, 1994
EuroQOL Group Website [online]. Available from URL: http://www.qlmed.org/EUROQOL/EUROQOL.html [Accessed 1999 Apr 15]
Apolone G, Mosconi P. The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 1998; 51: 1025–36
Lucioni C, Garancini MP, Massi-Benedetti M, et al. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmacoeconomics (Italian Research Articles) 2000; 2: 1–21
Miller Jr R. Simultaneous statistical inference. New York: Springer-Verlag, 1981
Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53–72
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365–76
Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12 (3): 199–220
Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51 (11): 1115–28
Dorman P, Slattery J, Farrell B, et al. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke 1998; 29 (1): 63–8
Myers C, Wilks D. Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Qual Life Res 1999; 8 (1–2): 9–16
Acknowledgements
Four educational meetings for the hospital pharmacists involved in the project were funded in part by Eli-Lilly, Spa, Italy.
The list of study participants includes the study coordinators (Trippoli S, Vaiani M, Messori A, Società Italiana di Farmacia Ospedaliera; Lucioni C, Istituto di Economia Sanitaria, Milano), the 19 participants at the Seminar ‘Master 2 in Farmacoeconomia’ (Firenze, 11-12 May 1999, 15-16 June 1999 and 21-22 September 1999; Roma, 15 December 1999) and the clinicians who were responsible for patient recruitment and quality-of-life interviews. The names and addresses (all towns/cities in Italy) of seminar participants and clinicians involved in the project were the following: Basadonna O, Rampazzo R, Gaion F, Morabito A, Sorarù M (Camposampiero, Padova); Becagli P, Panella M (Prato); Bianco MT, Marsili S (Siena); Burlon N, Medici M, Paccagnella A (Mestre, Venezia); Cannas A, Massidda B (Cagliari); Costantini M, Di Turi R, Cipri A, De Marinis F, Portalone L (Roma); Forresu MC, Staico G, Ortu S (Olbia, Sassari); Guido MA, Meo AT, Squillacioti A, Anania AM, Bagnato S, Prantera T (Crotone); Millevoi G, Iop A (Palmanova, Udine); Pistolesi C, Santo A, Bassetto A, Cetto, GL, Durante E (Verona); Rinaldi M, Pennucci C, Spinelli I (Carrara); Scanavacca P, Ballerin L, Indelli M (Ferrara); Sovernigo G, Bianco A (Conegliano Veneto, Treviso); Spoldi L, Arnoldi E, Comelli A (Seriate, Bergamo); Lopes Pegna A (Firenze).
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Trippoli, S., Vaiani, M., Lucioni, C. et al. Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer. Pharmacoeconomics 19, 855–863 (2001). https://doi.org/10.2165/00019053-200119080-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200119080-00007